Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04403282 · ClinicalTrials.gov registry record · Phase 4
Topical Eflornithine for Pseudofolliculitis Barbae: Randomized Controlled Trial
A Phase 4 study, sponsored by Walter Reed National Military Medical Center.
- Terminated
- Registry status
- Phase 4
- Development phase
- 9
- Enrollment target
NCT04403282 is a Phase 4 study that was terminated before completion, run by Walter Reed National Military Medical Center. The registered enrollment target is 9 participants.
The verdict
NCT04403282, a Phase 4 study, was terminated before completion, sponsored by Walter Reed National Military Medical Center.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 9 participants
- Enrollment target
Study Summary
To study the efficacy of topical eflornithine for pseudofolliculitis barbae from a quality of life standpoint and with objective physician-measured lesion counts. Our hypothesis is that the hair growth retardation that occurs with eflornithine will perhaps reduce the frequency over time that service members need to shave which could improve the formation of PFB lesions.
Interventions
- DRUG Eflornithine Topical
- DRUG Placebo Eflornithine Topical
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2020-09-27 |
| Est. Completion | 2023-06-22 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04403282
The ClinicalTrials.gov registry entry for NCT04403282 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Walter Reed National Military Medical Center, which has 48 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Eflornithine Topical is the first listed.
NCT04403282 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04403282 about?
NCT04403282 is a clinical study titled "Topical Eflornithine for Pseudofolliculitis Barbae: Randomized Controlled Trial". To study the efficacy of topical eflornithine for pseudofolliculitis barbae from a quality of life standpoint and with objective physician-measured lesion counts. Our hypothesis is that the hair growth retardation that occurs with eflornithine will perhaps reduce the frequency over time that service...
What is the current status of trial NCT04403282?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 9 participants. The study started on 2020-09-27. Estimated completion is 2023-06-22.
What interventions are being tested in trial NCT04403282?
The interventions under investigation include: Eflornithine Topical (DRUG), Placebo Eflornithine Topical (DRUG).
Who is sponsoring clinical trial NCT04403282?
This trial is sponsored by Walter Reed National Military Medical Center, which has 48 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.